A second argument in favour of direct stimulation of upper-gut L-cells is the observation that the release of GIP is closely related to that of GLP-1, even at an intra-individual level, indicating that some individuals have a poor response of GIP and GLP-1, and others have average or higher release of both incretin hormones [20]
When FDA-approved (expected 2027-2028), the commercial list price is projected at $1,000-1,500/month, though manufacturer savings programs may reduce out-of-pocket costs to $25-50/month for insured patients
Dosing adjusted to your response
This macronutrient distribution supports satiety and metabolic health independent of supplement use
4.4 Role of GLP-1 RAs in arrhythmias and stroke A meta-analysis by Liu et al
You will be seen first by one of our medical professionals for a consultation to determine if a GLP-1 medication is right for you